Drugs for Neglected Diseases initiative - DNDi
Isabela Ribeiro has extensive experience in the field of infectious diseases, currently serving as the Director of the Viral Diseases Cluster at the Drugs for Neglected Diseases initiative (DNDi) since 2005. In addition to this role, Isabela Ribeiro holds positions as Head of the Dynamic Portfolio Unit and Head of the Chagas Clinical Program, along with a history as a Senior Project Manager. Prior to joining DNDi, Isabela Ribeiro worked as a Consultant for TDR at the World Health Organization from 1996 to 2005. Isabela Ribeiro's educational background includes a medical degree from the Federal University of Rio de Janeiro, followed by internships and residencies in Internal Medicine at Beth Israel Medical Center and The Ohio State University, where Isabela Ribeiro also completed fellowship training in Infectious Diseases.
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.